<DOC>
	<DOCNO>NCT00948675</DOCNO>
	<brief_summary>The purpose study compare regimens pemetrexed , carboplatin pemetrexed maintenance paclitaxel , carboplatin , bevacizumab bevacizumab maintenance participant Stage IV nonsquamous non-small cell lung cancer .</brief_summary>
	<brief_title>Study Participants With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>This multicenter , randomize , open-label , Phase III trial . Eligible participant randomize 1:1 ratio receive pemetrexed carboplatin follow pemetrexed paclitaxel , carboplatin , bevacizumab follow bevacizumab study treatment . Participants randomize Pemetrexed + Carboplatin + Pemetrexed receive folic acid , vitamin B12 , dexamethasone state pemetrexed label . Before administration paclitaxel , participant randomize Paclitaxel + Carboplatin + Bevacizumab receive premedication ( dexamethasone , diphenhydramine , cimetidine ranitidine ) recommend paclitaxel label .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>histologic cytologic diagnosis advance nonsmall cell lung cancer ( NSCLC ) [ Stage IV American Joint Committee Cancer Staging Criteria ( AJCC ) stag system , version 7.0 , include M1a M1b ] , predominantly squamous cell histology , amenable curative therapy . Participants may receive prior systemic chemotherapy , immunotherapy , target therapy , biological therapy , include adjuvant therapy , stage NSCLC . prior radiation therapy allow &lt; 25 % bone marrow ; however , prior radiation whole pelvis allow . good performance status . adequate organ function . estimate life expectancy least 12 week . known central nervous system ( CNS ) disease , treat brain metastasis . major surgical procedure , open biopsy , open pleurodesis , significant traumatic injury within 28 day prior study anticipate need major surgery study . core biopsy minor surgical procedure , exclude placement vascular access device , close pleurodesis , thoracentesis , mediastinoscopy , within 7 day prior study . history gastrointestinal fistula , perforation , abscess , inflammatory bowel disease , diverticulitis . currently receive ongoing treatment fulldose warfarin equivalent significant vascular disease within 6 month prior Day 1 Cycle 1. evidence bleed diathesis coagulopathy . serious concomitant systemic disorder , opinion investigator , would compromise participant 's ability adhere protocol . serious cardiac condition , myocardial infarction , angina , heart disease . inadequately controlled hypertension . prior history hypertensive crisis hypertensive encephalopathy . serious , nonhealing wound , active ulcer , untreated bone fracture . another active malignancy , superficial basal cell superficial squamous ( skin ) cell , carcinoma situ cervix within last 5 year . previously receive treatment paclitaxel , carboplatin , pemetrexed , bevacizumab ( prior intravitreal administration bevacizumab preclude study participation ) . pregnant breastfeeding . history stroke transient ischemic attack within 6 month prior study . know sensitivity component paclitaxel , carboplatin , pemetrexed , bevacizumab . history hemoptysis within 3 month prior randomization . unable interrupt aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) . unwilling take folic acid vitamin B12 supplementation . clinically significant thirdspace fluid collection , example , ascites pleural effusion control drainage . Participants M1a disease pleural effusion eligible effusion adequately control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Advanced Non-Small Cell Lung Cancer Nonsquamous Histology</keyword>
	<keyword>Advanced Lung Cancer</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Lung Cancer</keyword>
</DOC>